As demand for precision medicine accelerates, CAR T and CAR Treg cell therapies are emerging as crucial tools in the fight against cancer and autoimmune diseases. For Thomas Fellner, PhD, head of ...
As demand for CAR T therapies strain traditional manufacturing, Autolus Therapeutics has tapped Cellares to evaluate whether that company’s automated Cell Shuttle platform can support expanded ...
Cellares and Cabaletta Bio have reached a key clinical milestone. The companies announced April 14 dosing the first two patients with rese-cel. Cellares’ automated Cell Shuttle platform manufactured ...
Fresenius and Charles River Laboratories are among 18 academic, research, industry and clinical partners that have formed a new European Union-supported consortium to develop an automated, ...
See more of our trusted coverage when you search. Prefer Newsweek on Google to see more of our trusted coverage when you search. For decades, advanced medical breakthroughs have followed a familiar ...
Avantor Inc. (NYSE:AVTR) is one of the best large cap stocks to buy under $20. On October 15, Avantor announced a partnership with BlueWhale Bio, which is a commercial-stage company that transforms ...
RADNOR, Pa. and PHILADELPHIA, Oct. 15, 2025 /PRNewswire/ -- Avantor, Inc. (AVTR) (NYSE: AVTR), a leading global provider of mission-critical products and services to customers in the life sciences and ...
Chimeric antigen receptor T cell (CAR T) therapies have transformed the treatment of blood cancers, delivering durable responses in patients with limited options. But CAR T therapies are complex and ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results